Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31645646 | 0.91 | P2RX7 (0.51) | P2RX7MAPK1QDPR | |
| SCHEMBL378063 | 0.88 | P2RX7 (0.46) | P2RX7MAPK1ROCK1 | |
| SCHEMBL31646076 | 0.87 | P2RX7 (0.53) | P2RX7MAPK1QDPRNOTUMPTAFR | |
| SCHEMBL2037752 | 0.87 | P2RX7 (0.45) | P2RX7MAPK1 | |
| SCHEMBL12294233 | 0.87 | P2RX7 (0.45) | P2RX7MAPK1QDPR | |
| SCHEMBL22445252 | 0.85 | QDPR (0.38) | P2RX7QDPRNOTUMALDH1A1HPGD | |
| SCHEMBL31078532 | 0.84 | P2RX7 (0.41) | P2RX7MAPK1QDPRNOTUMSMN1; SMN2 | |
| SCHEMBL19015869 | 0.84 | P2RX7 (0.43) | P2RX7MAPK1NAMPT | |
| SCHEMBL22657130 | 0.84 | P2RX7 (0.43) | P2RX7MAPK1ALDH1A1 | |
| SCHEMBL31646251 | 0.84 | P2RX7 (0.43) | P2RX7MAPK1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747253-A1 | SPIROCYCLIC WRN HELICASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-119528901-B | Thiazole compound, dessumo and/or deubiquitinase inhibitor, and preparation methods and applications thereof | Shanghai tongji hospital (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250340542-A1 | THYROID HORMONE RECEPTOR AGONISTS | INVENTISBIO CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| WO-2025226862-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057126-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | P2RX7 840/4885MAPK1 2199/4885QDPR 336/4885 |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | P2RX7 941/4885MAPK1 26/4885QDPR 2324/4885 |
| US-20250340542-A1 | THYROID HORMONE RECEPTOR AGONISTS | TSHR, THRA, TRHR | P2RX7 2087/4885MAPK1 1700/4885QDPR 3571/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | P2RX7 183/4885MAPK1 1807/4885QDPR 92/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | P2RX7 147/4885MAPK1 2298/4885QDPR 17/4885 |
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | P2RX7 3225/4885MAPK1 4689/4885QDPR 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.